Immuron Submits Phase 2 Study Report to FDA, Prepares for End-of-Phase 2 Meeting, Takes Next Step Toward Phase 3 Trial

Immuron Limited ((ASX: IMC, NASDAQ:IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it has submitted the Clinical Study Report to the U.S. Food and Drug Administration (FDA) for the recently completed Phase 2 study and will soon request an end of Phase 2 meeting which is a pre-cursor to proceeding to Phase 3.